VIENNA, Sept. 30 /PRNewswire/ — Intercell AG (VSE: ICLL) today
announced that effective October 1, 2010, Staph Leavenworth Bakali
will join its Management Board as Chief Business Officer with key
responsibilities for the commercial aspects of the Company,
directly leading Marketing and Sales, Corporate and Business
Development, and Alliance Management. Staph will also play a key
role with the other Management Board members in helping drive
forward the Company’s strategy. Prior to the appointment to
Intercell AG’s Management Board, Staph had stepped down from his
position as member of the Supervisory Board of the company.
“Staph has an outstanding track record in the vaccines industry
and has made major contributions to the success of some key
vaccines businesses globally. His commercial and strategic
experience ideally complement the skills of our current Management
Board,” said Gerd Zettlmeissl, Chief Executive Officer of Intercell
AG. “We are proud to have Staph working with us towards the next
growth phase of our Company.”
“Having been a member of Intercell’s Supervisory Board for
almost five years, I have been impressed with the progress and
capabilities of the Company and its people in creating value
through innovation, industrialization and commercialization,” said
Staph Bakali. “I am delighted to join a very dynamic team and look
forward to helping develop the business further.”
Staph brings 20 years of vaccine industry experience from his
previous leadership positions. He was recently Chief Executive
Officer of Genocea Biosciences, a Boston (U.S.) based innovative
biotech vaccine company, and previously Chief Operating Officer for
ID Biomedical (Vancouver, Canada) and PowderJect (Oxford, UK),
which were acquired by GlaxoSmithKline and Chiron, respectively.
Staph Bakali was also previously head of Sales and Marketing for
Chiron’s global vaccine business and SmithKline Beecham’s Vaccine
Business Unit in France. Staph holds a Masters d
‘/>”/>
